CLINICAL_TRIALS ClinicalTrials.gov record update

Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02706691
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:20.083534+00:00
Published At: 2019-04-10T00:00:00+00:00
Record Updated At: 2019-04-16
Results Posted At: 2019-04-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["FGFR Gene Amplification", "FGFR1 Gene Amplification", "FGFR2 Gene Amplification", "FGFR2 Gene Mutation", "FGFR3 Gene Mutation", "Head and Neck Squamous Cell Carcinoma", "Human Papillomavirus Infection", "Recurrent Head and Neck Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2019-04-16"
protocolSection.identificationModule.nctId: "NCT02706691"
protocolSection.identificationModule.officialTitle: "Phase IIa Study of the Efficacy of Single Agent BGJ398 (Infigratinib) in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-04-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.